Haleon launches with purpose to deliver better everyday health with humanity

With the demerger from GSK plc (GSK) now complete, maker of Sensodyne, Voltaren and Panadol becomes one of the world’s leading independent consumer health companies.

18 JULY 2022: Today, Haleon (LSE/NYSE: HLN) launches as an independent company 100% focused on consumer health, completing its demerger from GSK. The newly listed business is driven by its purpose to deliver better everyday health with humanity.Trading commenced on Monday on the London Stock Exchange (LSE), with Brian McNamara, CEO of Haleon, leading the opening ceremony to signal the start of trading. Trading on the New York Stock Exchange (NYSE) is set to follow¹, and a similar market-opening event will take place on Wednesday 20 July 2022.

Haleon has a world-class portfolio of brands including Sensodyne, Voltaren and Panadol, and will continue to develop category leading brands that address real consumer health needs, while focusing on future innovation across its entire portfolio.

With an increased consumer focus on health and wellness, an ageing global population, an emerging middle class in high-growth economies, growing self-care in the face of increased pressure on public healthcare systems and sizeable unmet consumer needs, Haleon has launched at a time when the consumer healthcare market is set for expansion (expected to be at a rate of 3-4% per annum over the medium-term). Haleon expects to deliver medium-term annual organic revenue growth of 4-6%.

Despite huge improvements in medicine, data and technology, everyday health remains elusive for too many people. Haleon aims to change this through a two-pronged approach. First, by working to remove barriers to better everyday health, and second, by aiming to empower 50 million people a year by 2025 to be more included in opportunities for better everyday health.

The company’s competitive advantage lies in its ability to blend deep human understanding and trusted science in the products it creates. Haleon is further distinguished by leading consumer healthcare-focused scientific capabilities, a well-developed organisational understanding of human health behaviours, strong capabilities in brand building, innovation and digital commerce and a powerful route-to-market.

The brands within the Haleon portfolio have been providing treatment and improving the quality of life for millions of consumers across the globe for decades. They have also been trusted, recognised, and recommended by healthcare professionals across multiple markets.

Brian McNamara, Chief Executive Officer, Haleon, said:

“This is a significant milestone for Haleon. Guided by our clear purpose and with a world class portfolio of brands that people know and trust, we stand ready to help address consumer needs and make better everyday health more achievable, inclusive and sustainable.

“Consumer health has never been more important than it is today, and I am delighted that Haleon, as an independent company, is ready to pursue our ambitions.”

“Today follows a huge amount of effort, planning and collaboration by our dedicated colleagues all around the world.”

Haleon (pronounced "Hay-Lee-On") was unveiled as the name of the business in February 2022 and is inspired by the merging of the words 'Hale', which is an old English word meaning 'in good health' and Leon, which is associated with the word 'strength'.

The company’s signature “For Health. With Humanity” brings to life the essence and purpose of Haleon and was developed by its own colleagues.